Back to top

Image: Bigstock

DOCS Expands Clinical AI Tools Across Three Major U.S. Health Systems

Read MoreHide Full Article

Key Takeaways

  • DOCS expands its AI partnership with NewYork-Presbyterian, Columbia University and Weill Cornell Medicine.
  • DOCS' Ask tool will integrate with Epic, giving clinicians access to clinical data and medical literature.
  • Doximity Scribe supports patient notes, dictation and pre-charting through mobile and desktop devices.

Doximity (DOCS - Free Report) recently announced an expansion of its collaboration with NewYork-Presbyterian, Columbia University and Weill Cornell Medicine to provide clinical staff across all three institutions with its AI-powered clinical decision support and documentation tools. The expanded offering includes Doximity Ask, a HIPAA-compliant clinical decision support tool, and Doximity Scribe, which helps clinicians generate patient notes, capture dictations and complete pre-charting through their phones or desktops.

Per management, Doximity is proud to have supported NewYork-Presbyterian in delivering quality patient care since 2021. The expanded collaboration will provide teams across NewYork-Presbyterian, Columbia and Weill Cornell Medicine access to Doximity’s full suite of AI tools, enabling them to communicate with patients, document care and manage treatment within a unified workflow.

DOCS Stock Trend Following the News

Shares of DOCS have inched up 0.4% since the announcement on Friday. Year to date, the stock has lost 24.7% against the industry’s 17% growth and the S&P 500’s 9.5% rise.

The expanded collaboration could strengthen DOCS' growth prospects by increasing the adoption of its AI-powered solutions across prominent academic healthcare institutions. Integrating its tools into established clinical workflows may improve product engagement and demonstrate their value in large-scale healthcare settings. Successful adoption could also enhance Doximity's appeal among other hospital systems seeking to modernize clinical operations, creating opportunities to broaden its enterprise customer base for its digital solutions. The agreement further reinforces the company's position in the growing market for AI-enabled healthcare technology.

DOCS currently has a market capitalization of $5.95 billion.

Zacks Investment Research
Image Source: Zacks Investment Research

More on the News

Doximity Ask will be accessible through the Epic electronic health record system used across all three institutions. The tool will allow clinicians to retrieve clinical information and reference medical literature within their existing workflows. Doximity Scribe will assist with clinical documentation by generating patient notes during visits, capturing dictations while clinicians are on the move and supporting pre-charting through mobile and desktop devices.

The expanded collaboration builds on NewYork-Presbyterian's use of Doximity Dialer since 2021, which supports remote audio and video appointments between physicians and patients. By adding clinical decision support and documentation capabilities, the partnership extends Doximity's presence across more stages of the clinical workflow. Physicians participating in residency training programs will also gain access to the tools after meeting specified training milestones.

The collaboration reflects a joint effort to simplify clinical workflows and improve access to relevant medical information at the point of care. By combining patient communication, documentation and clinical decision support capabilities, the institutions aim to reduce administrative friction and allow clinicians to devote more time to patient care.

Industry Prospects Favoring the Market

According to Grand View Research, the global artificial intelligence in clinical decision support market is estimated to reach $1.5 billion in 2026 and is projected to witness a CAGR of 17.1% through 2033.

Factors such as the increasing adoption of electronic health records (EHRs), rising demand for AI-powered clinical decision-making, growing need to improve clinical workflow efficiency, increasing focus on value-based care and advancements in generative AI technologies are driving market growth.

Other News

Doximity recently launched DoseCheck, a free safety feature within Doximity Ask that verifies AI-generated drug dosing recommendations against a structured database, FDA labeling and professional guidelines. The tool reduces dosing errors by more than 99%, improving accuracy to over 99%. DoseCheck is now available to all Doximity Ask users across mobile and desktop.

Doximity recently announced an extension of its 13-year partnership with U.S. News & World Report, strengthening its role in helping patients find physicians and schedule appointments. The company will continue providing physician data for U.S. News' Doctor Finder, supporting its Patient Connect appointment-booking tools. DOCS will also continue to serve as the exclusive third-party provider of the Expert Opinion physician survey used in the Best Hospitals and Best Children's Hospitals rankings.

DOCS’ Zacks Rank & Key Picks

Currently, Doximity carries a Zacks Rank #4 (Sell).

Some top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .

Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.

Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.

Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.

West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.

WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.

Published in